Semaglutide price in South Africa: what changed in 2026

Why is there no single semaglutide price in South Africa?

Because semaglutide is not one product. The same molecule is registered here under different names, for different jobs, at different doses: Ozempic and its authorised copy Extensior for type 2 diabetes, a new generic for the same condition, and Wegovy for chronic weight management. Each product carries its own regulated price for each strength.

The registered job matters as much as the name. Ozempic, Extensior and the generic are diabetes medicines under their SAHPRA registrations, while Wegovy is the weight-management registration. Our guide to what semaglutide is and how it works covers the molecule itself; this page follows the money.

Why do Ozempic and Wegovy prices differ when both are semaglutide?

Mostly dose. Ozempic's routine weekly doses run from 0.25 mg to 1 mg, while Wegovy climbs to a 2.4 mg weekly maintenance dose, so a month at Wegovy maintenance contains more than double the semaglutide of the highest routine Ozempic dose. More active ingredient in a pen means a higher price for that pen.

The registrations shape the pricing conversation too. Ozempic is registered for type 2 diabetes, so its price sits inside diabetes care and scheme formularies. Wegovy carries the weight-management registration and is sold in five strengths that step up over about four months.

Both are dispensed as pens holding four weekly doses, so one pen is close to a month of treatment at its labelled strength. A per-milligram comparison between the two brands misleads more than it helps: the products treat different registered conditions on different dose ladders.

How is the semaglutide price in South Africa set?

Through the Single Exit Price system. The manufacturer registers one national price for each pen with the Department of Health, every pharmacy charges that same figure, and the only lawful addition is a capped dispensing fee. The same pen therefore costs much the same in Cape Town, Johannesburg or Gqeberha.

You can check any quote against the regulated price yourself. The Medicine Price Registry at mpr.gov.za publishes the Single Exit Price of every registered medicine, so a pharmacy quote should sit near the registry figure plus a reasonable fee. A quote far below it signals a seller outside the regulated supply chain, not a bargain.

Prices move on a regulated clock. Manufacturers may raise prices only within an annual adjustment approved by the health department, capped at 1.47% for 2026, down from 5.25% in 2025. Cuts run through the regulator too: a manufacturer that wants to charge less notifies it first, which is why announced reductions can take weeks to reach shelves.

What did published semaglutide prices show by mid-2026?

Published figures put a month of semaglutide roughly between R1,200 and R3,750, depending on the product and strength. Reuters carried Wegovy's manufacturer-announced prices in March 2026, and Business Day published the regulated prices of Ozempic and Extensior in July 2026. The table sets out the attributed numbers.

Two reading notes. The Single Exit Price excludes the pharmacy's capped dispensing fee, and shelf quotes include VAT, so till prices sit somewhat higher than the figures above. And Reuters reported that a further 12% cut to Wegovy's 1.7 mg dose was awaiting approval in March 2026, so the Wegovy numbers may have moved again since. We do not sell medicine. Prices vary by pharmacy and dose; confirm with your pharmacy.

The product-level detail sits in its own guides: how much Ozempic is in South Africa and how the Wegovy cost is set and why it has fallen.

Why did the semaglutide price fall in 2026?

Competition, on two fronts. Eli Lilly's tirzepatide, sold as Mounjaro, reached South Africa first and held 52% of the local market at the end of January 2026, according to sales figures reported by Reuters. Novo Nordisk answered with Wegovy price cuts in December 2025 and March 2026, and the second was the bigger move.

That March cut took the starting dose down by close to 40% and the maintenance dose down 27%. A local executive told Reuters the launch prices had not been suited to the South African market.

Demand explains the pressure. Spotlight reported that Ozempic jumped from 170th to 12th among the biggest medicine spending drivers tracked by the claims processor Mediscor between 2023 and 2024. A market that size attracts rivals, and rivals move prices. The second front, cheaper semaglutide itself, arrived in July 2026 and is covered next.

Is there a generic semaglutide in South Africa?

Yes, since July 2026. SAHPRA approved Sun Pharma's semaglutide injection that month, the first generic for South Africa, and Reuters reported the company planned to launch within days of the approval. It mirrors Ozempic's two pen sizes, and it is registered for type 2 diabetes, not for weight management.

No South African price for the generic had been published at the time of writing, but generics typically enter below the originator's regulated price. The timing follows the patent: Novo Nordisk's local semaglutide patent expired in March 2026, which is what opened the door to generic applications at all.

What the generic does not change: no generic semaglutide is registered for weight management here. The full story, including what a generic is and is not, sits in our generic Ozempic guide.

What is Extensior, the authorised Ozempic copy?

Extensior is Ozempic under another name. Novo Nordisk makes it with the identical active ingredient, manufacturing process and delivery device, and the Swiss firm Acino distributes it in South Africa. It launched in late July 2026 at a regulated price 15% below Ozempic's, and it is registered for type 2 diabetes.

An authorised copy is neither a generic nor a biosimilar: it is the originator's own product released under a second name, a move manufacturers make when generic competition approaches. It comes in the same 0.25 mg, 0.5 mg and 1 mg weekly doses as Ozempic, in the same pen.

Some doctors use semaglutide in this form off-label for weight management. Off-label use is a clinical decision a doctor weighs during assessment, and the registered weight-management option remains Wegovy. A 15% price gap does not change what each product is registered to treat.

How does your dose change the monthly semaglutide cost?

Every semaglutide plan starts low and steps up, so the monthly cost climbs across the first months even when no price list moves. One pen holds four weekly doses at its labelled strength, higher strengths cost more, and the maintenance dose is where a budget settles.

Budget for the strength you expect to hold, not the starting pen. Many people maintain on a middle dose where results and side effects balance, and where that is the doctor's call it also costs less than the top of the ladder.

Avoid stop-start treatment driven by money. Restarting after a long gap often means stepping up from a lower dose again, which pays for the climb twice. If cost is squeezing you, raise it at a review; stretching doses or splitting pens changes the treatment a doctor confirmed, and nobody should adjust a dose to fit a budget on their own.

Does medical aid cover semaglutide in South Africa?

Usually only for type 2 diabetes. Schemes that fund semaglutide mostly do so under chronic medicine benefits for diabetes, subject to formularies and pre-authorisation. For weight management, obesity is not a Prescribed Minimum Benefit condition, so most schemes exclude the medicine and most people pay out of pocket.

Cheaper semaglutide has not shifted that yet. Discovery Health told Business Day in July 2026 that the 15% saving on the authorised copy was a positive development that may improve affordability for some people, but not enough to justify broader scheme funding at this stage.

Medical savings accounts remain the practical route for many members, and scheme rules change year to year, so ask yours in writing. Our medical aid guide covers the questions worth asking and what to do with a no.

Is compounded semaglutide a cheaper way in?

No. Compounded semaglutide sold outside the registered supply chain is not a budget version of the medicine; it is an unregistered product with unverified contents, and in 2026 both the regulator and the courts moved against it. Treating it as a savings plan carries health and legal risk.

The enforcement was concrete. Health regulators warned against any continued use or dispensing of iDexis compounded semaglutide and tirzepatide products after a recall instruction, and in June 2026 the High Court in Pretoria granted Novo Nordisk an interim interdict stopping the compounding pharmacy group from producing and marketing them. The company has applied for leave to appeal, so the litigation continues.

Whatever the appeal decides, the practical warning stands: only a licensed pharmacy may lawfully dispense semaglutide, and no unregistered product has verified contents. Suspicious sellers can be reported to SAHPRA's 24-hour hotline on 0800 204 307.

How does semaglutide pricing compare with tirzepatide?

The two molecules overlap in a broadly similar monthly band at standard doses. The medicines run on different dose ladders under different registrations, so a straight rand-for-rand comparison hides as much as it shows.

Published tirzepatide figures and what drives them are covered in our tirzepatide price guide. Price belongs at the end of the comparison, after trial results, side-effect profiles, availability and your medical history, and the right option is decided by a doctor on assessment.

What could change the semaglutide price next?

More competition, mostly pushing down. The local patent expired in March 2026, the first generic approval and the authorised copy landed within a fortnight of each other in July, and nothing stops further manufacturers from applying now. Nothing is promised either: no further cuts had been announced at the time of writing.

Tablets are the other question people price. No semaglutide tablet is registered in South Africa: the Wegovy pill approved overseas has no local registration, and Rybelsus, the diabetes tablet registered here in 2024, has never been launched. So no lawful South African tablet price exists, and any rand figure quoted locally for semaglutide tablets is invented.

Prices in this class also age quickly. Two cuts, a court case, a copy and a generic all landed within twelve months, so check the date on any figure you read, this article included.

Costs aside: suitability comes before price

Whether semaglutide suits you decides more than any price list does. The common side effects are digestive: nausea, vomiting, diarrhoea and constipation, usually worst around dose increases and easing as the body adjusts. How well any dose is tolerated differs from person to person.

Some people should not use it at all. Semaglutide is not suitable in pregnancy or while breastfeeding, or for anyone with a personal or family history of medullary thyroid cancer or MEN2 syndrome, and a history of pancreatitis needs a careful medical decision. Severe, persistent stomach pain on treatment can signal pancreatitis: seek medical care immediately.

Every product on this page is Schedule 4, so treatment starts with a doctor's assessment and authorisation and ends at a licensed pharmacy, with reviews and sometimes blood tests along the way that belong in the budget. How doctor-led treatment works explains the steps.

Frequently asked questions